Guangxiang Pharmaceutical Group’s “Challenge-Based Recruitment” Project for Tackling Key Core Technologies and Products in the Industrial Sector of One Province

Recently, the Hebei Provincial Department of Industry and Information Technology announced the first batch of key core technologies and products in the industrial sector selected under the “Challenge-based Recruitment” initiative, along with the entities that have taken on these challenges. Shijiazhuang Sihua Pharmaceutical Group’s Hebei Guangxiang Pharmaceutical Co., Ltd. has been designated as the lead entity for the project titled “R&D and Industrialization of the Synthesis Process for Nicethamide API.”

The Group’s Bosheng Medical Devices, Pharmaceuticals, and Packaging Materials Research Institute Officially Established

On the morning of January 6, the Pharmaceutical Packaging Materials Research Institute of Shijiazhuang Sihua Pharmaceutical Group’s Jiangsu Bosheng Medical New Materials Co., Ltd. was abuzz with guests and filled with a festive atmosphere as the institute’s inauguration ceremony was solemnly held.

Shijiazhuang Sihua Pharmaceutical Selected for the First Batch of the National “Thousand Enterprises, Hundred Cities” Initiative to Enhance Trademark and Brand Value

Recently, the National Intellectual Property Administration announced the first batch of enterprises, regional trademarks, and trademark guidance stations under the “Thousand Enterprises in One Hundred Cities” Initiative for Enhancing Trademark and Brand Value, with Shijiazhuang Sihua Pharmaceutical Co., Ltd. included on the list of enterprise trademarks.

Three Products of Shijiazhuang Sihua Pharmaceutical Recognized as Among the First Batch of Patent-Intensive Products in China

Recently, the national pilot platform for the registration and recognition of patent-intensive products released the first list of such products, with sodium bicarbonate injection, bromhexine hydrochloride glucose injection, and sodium chloride injection manufactured by Shijiazhuang Sihua Pharmaceutical Co., Ltd. successfully making the cut.

Guangxiang Pharmaceutical Group Obtains Cangzhou City’s First “Carbon Certificate”

On March 13, Cangzhou City held a certificate-awarding ceremony for the carbon footprint report at Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, presenting the city’s first carbon footprint report certification to Guangxiang Pharmaceutical. This milestone underscores the company’s significant achievements in advancing the “dual carbon” goals and realizing green development.

A Position at Shijiazhuang Sihua Pharmaceutical Awarded the National Model Youth Safety Production Post Title

Recently, the Central Committee of the Communist Youth League and the Ministry of Emergency Management jointly issued a notice recognizing 486 organizations as National Model Posts for Youth Safety in Production for 2023 and launching the initiative to establish such posts for 2024. The packaging position in the Solid Dosage Workshop No. 207 at Shijiazhuang Sihua Pharmaceutical was awarded the title of National Model Post for Youth Safety in Production for 2023.

The Group Has Deployed the “2024 Quality Improvement Year” Initiative

In accordance with the requirements set forth in the operational work report adopted by the Employees’ Congress and the work plans of the Group Party Committee and the Trade Union, the Group has designated 2024 as the “Year of Quality Enhancement.” Recently, Shijiazhuang Sihua Pharmaceutical Group made arrangements and deployments for the in-depth implementation of the “2024 Year of Quality Enhancement” initiative.

The Group has been ranked among the Top 100 Chinese Chemical Pharmaceutical Companies, climbing five places from the previous year.

At the MSCI Star Awards ceremony on the evening of June 25, the MSCI Organizing Committee unveiled the highly anticipated “2023 Top 100 Chinese Pharmaceutical Companies” series of rankings. Thanks to its outstanding innovation capabilities, robust product quality, and steady market influence, the Group was honored on the sub-ranking “2023 Top 100 Chinese Chemical Pharmaceutical Enterprises,” securing the 34th position—five places higher than the previous year.

The Group Ranked Among the Top 30 in the 2024 China Pharmaceutical R&D Comprehensive Strength Ranking

On July 4, the 9th China Pharmaceutical R&D Innovation Summit 2024 was grandly inaugurated at the Xiong’an New Area Convention and Exhibition Center. Shijiazhuang Sihua Pharmaceutical Group was recognized in two prestigious rankings—the “Top 100 Chinese Pharmaceutical R&D Comprehensive Strength List 2024” and the “Top 100 Chinese Chemical Pharmaceutical R&D Strength List 2024”—ranking 28th and 12th, respectively. In addition, Xia Guolong, Deputy General Manager of the Group’s R&D Center, was honored as a “2024 Leading Figure in Chinese Pharmaceutical Innovation.”

The group has now passed evaluation for over 100 products.

On August 13, Shijiazhuang Sihua Pharmaceutical Group’s applications for two products—the Class 3 chemical drug sodium-potassium-magnesium-calcium concentrated injection solution and the Class 4 chemical drug levodopa-benserazide tablets—received drug production registration approvals from the National Medical Products Administration on the same day, and were deemed to have passed the bioequivalence evaluation. To date, the Group has had 100 generic drug varieties comprising 133 specifications either pass or be deemed to have passed the bioequivalence evaluation, bringing the total number of evaluated products to 100—a figure that places the Group among the leaders in the pharmaceutical industry and lays a solid foundation for promoting the company’s high-quality development.

The Group Achieves a Double Crown of Team and Individual Titles in the Provincial Injection Manufacturing Skills Competition Finals

The finals of the 2024 Hebei Provincial Workers’ Vocational Skills Competition—Injection Manufacturing Category, themed “Moving Forward with Innovation, Achieving Long-Term Success Through Technology,” concluded successfully on the morning of October 18. Outstanding contestants selected by Shijiazhuang Sihua Pharmaceutical Group showcased their exceptional skills in the competition and clinched both the team and individual championships, bringing great honor to their company.

A Project of the Group Selected as an Outstanding Smart Manufacturing Scenario at the National Level

Recently, the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Ministry of Finance, and the State Administration for Market Regulation jointly released the list of demonstration smart manufacturing factories and outstanding application scenarios for 2022. The digital product R&D and design project submitted by Shijiazhuang Sihua Pharmaceutical Co., Ltd. was selected as an outstanding smart manufacturing scenario for 2022.

Guolong Pharmaceutical of the Group Recognized as a Quality Benchmark among Industrial Enterprises in Hebei Province

Recently, the Hebei Provincial Department of Industry and Information Technology released the 2022 List of Quality Benchmarks for Industrial Enterprises in Hebei Province. Following a rigorous process that included enterprise applications, local recommendations, expert reviews, deliberations, and public announcement on the department’s website, the Group’s Guolong Pharmaceutical was recognized as a 2022 Quality Benchmark for Industrial Enterprises in Hebei Province for its proven best practices in comprehensive quality management based on green manufacturing of active pharmaceutical ingredients.

Guangxiang Pharmaceutical Group Recognized as a Hebei Province Model Enterprise for Technological Innovation

On January 6, the Hebei Provincial Department of Industry and Information Technology announced the list of provincial technology innovation demonstration enterprises for 2022. A total of 36 companies, including Hebei Guangxiang Pharmaceutical Co., Ltd. of the Group, were recognized by the department as provincial technology innovation demonstration enterprises for 2022.

Ninety-six products of the group have been included in the National Essential Medicines List.

On January 18, the National Healthcare Security Administration announced the results of the adjustment to the National Reimbursement Drug List and released the new edition of the list. The updated “National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2022)” includes a total of 2,967 drugs, comprising 1,586 Western medicines and 1,381 traditional Chinese patent medicines. Shijiazhuang Sihua Pharmaceutical Group has had 96 products included in the National Essential Medicines List.

Guangxiang Pharmaceutical Group Recognized as a National-Level Green Factory

On March 23, the General Office of the Ministry of Industry and Information Technology released the 2022 Green Manufacturing List, which included Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group. This marks the second green factory under the group’s umbrella to be recognized, following Shijiazhuang Sihua’s inclusion in the MIIT’s first batch of Green Manufacturing Demonstration Enterprises in 2017.

All five products in which the Group participated in the eighth round of national centralized procurement were successfully awarded.

On March 29, the highly anticipated eighth round of national centralized bulk procurement of pharmaceuticals was opened for bidding in Lingshui, Hainan Province. Shijiazhuang Sihua Pharmaceutical Group successfully won bids for all seven specifications across five new products it submitted: argatroban injection, ornidazole injection, metronidazole injection, felodipine II sustained- and controlled-release tablets, and mecobalamin injection.

A Group Employee’s Innovative Achievement Featured at the National Master Craftsmen Innovation Exchange Conference

On July 28, the Second Innovation Exchange Conference for National Master Craftsmen was held, at which Shijiazhuang Sihua Pharmaceutical Group’s “Development and Industrialization of Key Technologies for Vertical Polypropylene Infusion Bags” was showcased as a national trade union– and Hebei Province–level achievement in employee technological innovation. The project was awarded the National Federation of Trade Unions’ Outstanding Employee Technological Achievement Award and the Hebei Provincial Federation of Trade Unions’ Second Prize for Outstanding Employee Technological Innovation.

All four products in which the Group participated in the ninth round of national centralized procurement have been successfully awarded.

On November 6, the ninth round of national centralized bulk procurement of pharmaceuticals—highly anticipated by both the domestic pharmaceutical industry and the broader public—was opened for bidding in Shanghai. Shijiazhuang Sihua Pharmaceutical Group successfully won bids for all five specifications across four product categories it had submitted: azithromycin dry suspension, urapidil hydrochloride injection, tedizolid phosphate for injection, and sodium citicoline injection.

Shijiazhuang Sihua Pharmaceutical Named Among the Top 100 Chinese Pharmaceutical Companies of 2022

On the joyous occasion of Shijiazhuang Sihua Pharmaceutical Group’s 75th anniversary, the highly anticipated 40th National Pharmaceutical Industry Information Annual Conference and the 2022 Top 100 Chinese Pharmaceutical Companies Forum, held on November 18, solemnly unveiled a series of prestigious rankings, including the “2022 Top 100 Chinese Pharmaceutical Companies” and the “2023 Best Pharmaceutical R&D Pipeline Enterprise in China.” Shijiazhuang Sihua Pharmaceutical Group once again made the “Top 100 Chinese Pharmaceutical Companies” list, ranking 56th, and was also re-elected as one of the “2023 Best Pharmaceutical R&D Pipeline Enterprises in China.”

Shijiazhuang Sihua Pharmaceutical Recognized as a National Quality Benchmark Enterprise

On November 23, the China Association for Quality issued the “Notice on Announcing the Results of the Selection of Typical National Quality Benchmark Experiences for 2023,” under which Shijiazhuang Sihua Pharmaceutical Co., Ltd. was successfully recognized as a 2023 National Quality Benchmark Enterprise. This makes it the only pharmaceutical manufacturer nationwide to receive this honor this year.

Shijiazhuang Sihua Pharmaceutical Group Celebrates the 75th Anniversary of Its Founding

Seventy-five years of weathering storms and forging ahead; seventy-five years of relentless striving and progress. Recently, Shijiazhuang Sihua Pharmaceutical Co., Ltd., a leading enterprise in our city’s biopharmaceutical industry, celebrated the 75th anniversary of its founding.

Chinese Red Cross Dedication Medal

The Red Cross Society of China has specially awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the “Red Cross Society of China Dedication Medal.”

Top Ten Pharmaceutical Enterprises in Hebei Province

The Hebei Provincial Pharmaceutical Industry Association has awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “Top 10 Pharmaceutical Enterprises in Hebei Province for 2021.”

Hebei Province’s First Batch of “Whitelist Enterprises” in the Industrial Sector

Shijiazhuang Sihua Pharmaceutical Co., Ltd., Hebei Guolong Pharmaceutical Co., Ltd., and Hebei Guangxiang Pharmaceutical Co., Ltd. have been included in the first batch of Hebei Province’s “whitelist” of key industrial chain and supply chain enterprises.

Headline Power • Enterprise Recognized for High-Quality Development in China’s Pharmaceutical Industry

Shijiazhuang Sihua Pharmaceutical Co., Ltd. has been awarded the title of “Leading Force: Enterprise Recognized for High-Quality Development in China’s Pharmaceutical Industry.”

Hebei Province Emergency Supplies Production Capacity Reserve Base

The Hebei Provincial Department of Industry and Information Technology and the Hebei Provincial Development and Reform Commission have awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “Hebei Provincial Emergency Supplies Production Capacity Reserve Base.”

Jiangsu Bosheng Officially Listed on the Innovation Board of the National Equities Exchange and Quotations

The application for the public transfer of shares of Jiangsu Bosheng Medical New Materials Co., Ltd. has been reviewed and approved by the National Equities Exchange and Quotations Company, and the company has now been officially listed on the Innovation Layer of the NEEQ.

A Youth Collective from Shijiazhuang Sihua Pharmaceutical Awarded “Hebei Provincial Model Post for Youth Safety in Production”

Recently, the Hebei Provincial Committee of the Communist Youth League and the Hebei Provincial Emergency Management Department jointly issued the “Notice on Recognizing the 2021 Hebei Provincial Model Posts for Youth Safety in Production,” commending 84 such posts for the year 2021. The packaging position in Workshop 207 for Solid Preparations at Shijiazhuang Sihua Pharmaceutical Group was recognized as a “Hebei Provincial Model Post for Youth Safety in Production.”

Youyi Chemical Group Awarded “Hebei Provincial Green Factory”

Recently, the Hebei Provincial Department of Industry and Information Technology released the 2022 Hebei Province Green Manufacturing List, under which Shijiazhuang Sihua Pharmaceutical Group Cangzhou Lingang Youyi Chemical Co., Ltd. was recognized as a “Hebei Provincial Green Factory.”

National Intellectual Property Demonstration Enterprise

Recently, the National Intellectual Property Administration announced the results of the 2022 evaluation for National Intellectual Property Demonstration Enterprises and Advantage Enterprises, with Shijiazhuang Sihua Pharmaceutical Co., Ltd. being recognized as a National Intellectual Property Demonstration Enterprise.

National-level Manufacturing Single-Champion

Recently, the Ministry of Industry and Information Technology of the People’s Republic of China and the China Federation of Industrial Economics announced the seventh batch of Manufacturing Single-Champion Enterprises (Products), with Shijiazhuang Sihua Pharmaceutical Co., Ltd. recognized as a Manufacturing Single-Champion.

Top 100 Chinese Pharmaceutical Companies

On December 18, the National Pharmaceutical Industry Information Annual Conference, hosted by the China Pharmaceutical Industry Information Center under the Ministry of Industry and Information Technology, was held in Shanghai. Shijiazhuang Sihua Pharmaceutical Co., Ltd. was honored on the 2021 Top 100 Chinese Pharmaceutical Companies list, ranking 59th—up 13 places from the previous year—and once again secured the prestigious title of “Best Pharmaceutical R&D Pipeline Enterprise in China for 2022” for the third consecutive year.

Hebei Province Contract-Honoring and Credit-Keeping Enterprise

Shijiazhuang Sihua Pharmaceutical Co., Ltd. has been recognized by the Hebei Provincial Credit Association, the Enterprise Economic Promotion Association, and the Enterprise Credit Research Institute as a “Contract-Abiding and Credit-Respecting Enterprise” in Hebei Province.

Hebei Province’s Manufacturing Single-Champion Enterprises

The Hebei Provincial Department of Industry and Information Technology has awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “Provincial Manufacturing Single-Champion Enterprise for 2020.”

A-Level R&D Institution of Industrial Enterprises in Hebei Province

Hebei Guolong Pharmaceutical Co., Ltd. has been recognized by the Hebei Provincial Department of Industry and Information Technology as an R&D institution for industrial enterprises in Hebei Province, with an A rating.

Hebei Province’s “Specialized, Refined, Distinctive, and Innovative” SMEs

The Hebei Provincial Department of Industry and Information Technology has recognized Hebei Guangxiang Pharmaceutical Co., Ltd. and Hebei Guolong Pharmaceutical Co., Ltd. as “specialized, refined, distinctive, and innovative” small and medium-sized enterprises in Hebei Province.

Hebei Province “Specialized, Refined, Distinctive, and Innovative” Demonstration Enterprise

The Hebei Provincial Department of Industry and Information Technology has recognized Hebei Guangxiang Pharmaceutical Co., Ltd. and Hebei Guolong Pharmaceutical Co., Ltd. as model “specialized, refined, distinctive, and innovative” enterprises in Hebei Province.

China’s Best Industrial Enterprise for Pharmaceutical R&D Product Lines

The China Pharmaceutical Industry Information Center has awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “2021 Best Industrial Enterprise for Pharmaceutical R&D Product Lines in China.”

Top 100 Chinese Pharmaceutical Companies

The China Pharmaceutical Industry Information Center has awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “Top 100 Chinese Pharmaceutical Companies of 2020,” ranking it 72nd.

Top 100 Private Manufacturing Enterprises in Hebei Province

The Hebei Provincial Federation of Industry and Commerce has awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “Top 100 Private Manufacturing Enterprises in the Province.”

Hebei Provincial Enterprise Technology Center

Hebei Guangxiang Pharmaceutical Co., Ltd. has been recognized as the Hebei Provincial Enterprise Technology Center by the Hebei Provincial Development and Reform Commission, the Hebei Provincial Department of Science and Technology, the Hebei Provincial Tax Service of the State Taxation Administration, and Shijiazhuang Customs.

Top 20 of the Top 100 Private Enterprises in Hebei Province in Terms of Social Responsibility

The Hebei Provincial Federation of Industry and Commerce has awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “Top 20 among the Top 100 Private Enterprises in the Province for Corporate Social Responsibility.”

Hebei Province Demonstration Enterprise for Technological Innovation

The Hebei Provincial Department of Industry and Information Technology has recognized Hebei Guolong Pharmaceutical Co., Ltd. as a 2021 Hebei Provincial Demonstration Enterprise for Technological Innovation, ranking it 31st.

Advanced Unit for Emergency Management and Work Safety in 2019

In January, the Hebei Provincial Emergency Management and Work Safety Association awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “2019 Advanced Unit in Work Safety.”

“Star of the Fight Against the Epidemic”: The Most Socially Responsible Pharmaceutical Company

In May, Pharmaceutical Observer awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “‘Anti-Epidemic Star’ – Most Socially Responsible Pharmaceutical Enterprise.”

2019 Youth Volunteer Group

In May, the Communist Youth League Committee of Gaocheng District, Shijiazhuang City, awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “2019 Outstanding Youth Volunteer Group.”

New R&D Center Base Completed and Put into Use

In May, the new R&D center was completed and put into operation, boasting a scale and state-of-the-art facilities that lead the nation, marking a new historic phase in the Group’s innovative development.

“Anti-Pandemic, Charity, and Compassion” Enterprise

In August, the Pharmaceutical Industry Chamber of the All-China Federation of Industry and Commerce awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “Enterprise for Anti-Epidemic Efforts, Charity, and Compassion.”

Top 50 Growing Companies in China’s Pharmaceutical Industry

In August, the Pharmaceutical Industry Chamber of the All-China Federation of Industry and Commerce awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “Top 50 Growing Enterprises in China’s Pharmaceutical Industry.”

Top 100 Private Enterprises in Hebei Province, 2020

In September, the Hebei Provincial Federation of Industry and Commerce awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “Top 100 Private Enterprises in Hebei Province for 2020.”

Top 100 Private Manufacturing Enterprises in Hebei Province, 2020

In September, the Hebei Provincial Federation of Industry and Commerce awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “Top 100 Private Manufacturing Enterprises in Hebei Province for 2020.”

Top 100 Chinese Chemical Pharmaceutical Industry Enterprises by Overall Industrial Strength in 2020

In October, the China Association for Pharmaceutical Industry, the China Pharmaceutical Commercial Association, the China Over-the-Counter Drugs Association, the China Vaccine Industry Association, and Sinopharm Reed Exhibitions Co., Ltd. conferred upon Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “Top 100 Enterprises in Comprehensive Strength among Industrial Enterprises in China’s Chemical Pharmaceutical Industry for 2020.”

2020 Outstanding Brand of China’s Chemical Pharmaceutical Industry for Formulation Export

In October, the China Association for Pharmaceutical Industry, the China Pharmaceutical Commerce Association, the China Over-the-Counter Drugs Association, the China Vaccine Industry Association, and Sinopharm Reed Exhibitions Co., Ltd. conferred upon Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “2020 Outstanding Export-Oriented Formulation Enterprise Brand in China’s Chemical Pharmaceutical Industry.”

Top 100 Chinese Ethnic Medicine Brands of 2019

In October, the Pharmaceutical Industry Chamber of the All-China Federation of Industry and Commerce awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “Top 100 Chinese National Medicine Brands of 2019.”

Hebei Provincial Government Quality Award

In November, the Hebei Provincial Government awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the “Hebei Provincial Government Quality Award.”

Top 10 Pharmaceutical Enterprises in Hebei Province for 2019

In December, the Hebei Provincial Pharmaceutical Industry Association awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “Top 10 Pharmaceutical Enterprises in Hebei Province for 2019.”

Advanced Unit for Fire Safety Management in 2018

In January, the High-tech Zone plant of Shijiazhuang Sihua Pharmaceutical Co., Ltd. was awarded the title of “Advanced Unit for Fire Safety Management in 2018” by the High-tech Zone Fire Safety Committee.

First Prize for Scientific and Technological Progress of Hebei Province

The People’s Government of Hebei Province has awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the First Prize for Scientific and Technological Progress of Hebei Province.

National Enterprise Technology Center

The National Development and Reform Commission, the Ministry of Finance, and three other ministries have conferred the title of “National Enterprise Technology Center” on Shijiazhuang Sihua Pharmaceutical Co., Ltd.

National Demonstration Enterprise for Technological Innovation

The Ministry of Industry and Information Technology has awarded Shijiazhuang Sihua Pharmaceutical Co., Ltd. the title of “National Model Enterprise for Technological Innovation.”

Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of the company, launches its “Modernized Active Pharmaceutical Ingredient” project.

In 2017, the “Modernized Active Pharmaceutical Ingredient” project was launched at Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of the company.

The company has been recognized as a “first-batch National Green Factory.”

In 2017, the company was recognized as one of the “first batch” of national Green Factories.

The company has been approved to establish an “Academician Workstation.”

In 2017, Shijiazhuang Sihua Pharmaceutical Co., Ltd. was approved to establish an academician workstation.

National “Contract-Abiding and Credit-Respecting Enterprise”

In 2016, the company was recognized by the State Administration for Industry and Commerce as a “Contract-Honoring and Credit-Keeping Enterprise” at the national level for the 2014–2015 period.

The company has been approved to establish a “National-Local Joint Engineering Laboratory.”

In 2016, the company was approved by the National Development and Reform Commission to establish the “National–Local Joint Engineering Laboratory for Quality Control of Chemical Injectable Drugs.”

Establishment of the Pharmaceutical Research Institute

In 2015, the company established a Pharmaceutical Research Institute and was approved by the Ministry of Human Resources and Social Security to set up a postdoctoral research workstation.

The Company Acquires Jiangsu Bosheng Pharmaceutical New Materials Co., Ltd.

In 2015, the company acquired Jiangsu Bosheng Pharmaceutical New Materials Co., Ltd., injecting fresh vitality and momentum into the expansion of Shisi Pharmaceutical Group.

Reorganization of the subsidiary, Hebei Hanlin Biological Co., Ltd.

In 2015, the company restructured Hebei Hanlin Biotechnology Co., Ltd., thereby expanding into the biotechnology sector.

Company’s New Upright Pouch Infusion Product Officially Launched

In 2014, the company officially launched a new line of stand-up pouch infusion products, which feature upright positioning, automatic drainage, safety and environmental friendliness, and ease of operation. These products integrate all the advantages of both PP plastic-bottle infusions and non-PVC soft-bag infusions, effectively ensuring the quality and safety of pharmaceuticals while offering broader applicability.

Top 100 Chinese Pharmaceutical Companies

In 2014, the company was recognized by the Ministry of Industry and Information Technology of China as one of the “Top 100 Chinese Pharmaceutical Companies.”

National “Contract-Abiding and Credit-Respecting Enterprise”

In 2014, the company was for the first time recognized by the State Administration for Industry and Commerce as a “National Model Enterprise for Contract Compliance and Creditworthiness” for the 2012–2013 period.

Subsidiary Guolong Pharmaceutical Awarded the Title of “Hebei Provincial High-Tech Enterprise”

In 2014, Hebei Guolong Pharmaceutical Co., Ltd., a subsidiary of Siyao, was recognized as a “Hebei Provincial High-Tech Enterprise.”

National May Day Labor Award

The company has been awarded the “National May Day Labor Medal,” the highest collective honor for Chinese workers, by the All-China Federation of Trade Unions.

The company has successfully obtained its first new-version GMP certificate for intravenous solutions.

In 2012, the company obtained the National New-Generation GMP Certification for Workshop 208, which was the company’s first new-generation GMP certificate for intravenous solutions and positioned it among the earliest domestic enterprises to achieve this certification.

Groundbreaking Ceremony Held for the Relocation and Upgrade Project of Shijiazhuang Sihua Pharmaceutical Co., Ltd. Headquarters

In 2012, construction commenced on the headquarters relocation and upgrade project for Shijiazhuang Sihua Pharmaceutical Co., Ltd.

The company is constructing a modern formulation workshop and a corresponding automated logistics center.

In 2010, the company constructed a state-of-the-art pharmaceutical formulation workshop and an accompanying automated logistics center in accordance with EU certification standards.

The “Shimen” trademark has been recognized as the first well-known trademark in China’s intravenous infusion manufacturing sector.

In 2009, the company’s “Shimen” trademark was recognized by the Trademark Office of the State Administration for Industry and Commerce as a “Well-Known Trademark in China.”

Enterprise Credit Rating: AAA-Credit Enterprise

In 2009, the company was awarded an AAA credit rating, recognizing it as a creditworthy enterprise.

AAA-Level Harmonious Labor Relations Enterprise of Hebei Province

In 2009, the company was awarded the AAA-level title of “Harmonious Labor Relations Enterprise” in Hebei Province.

Soft-pack infusion production surpasses glass-bottle infusion production for the first time.

In 2008, the company’s production of flexible-packaging intravenous solutions surpassed that of glass-bottle intravenous solutions for the first time.

Shijiazhuang Sihua Pharmaceutical Co., Ltd. Successfully Lists on the Hong Kong Stock Exchange

Shijiazhuang Sihua Pharmaceutical Co., Ltd. has successfully listed its shares on the Hong Kong Stock Exchange.

Top 100 Chinese Pharmaceutical Manufacturing Enterprises

The company has ranked among the Top 100 pharmaceutical enterprises in China, holding the 78th position.

Hebei Province High-tech Enterprise

The company has been recognized as a “Hebei Provincial High-Tech Enterprise.”

The flexible-packaging infusion project has been established and commenced construction in the Liangcun Economic and Technological Development Zone in Shijiazhuang.

In January 2002, the company’s RMB 250 million soft-pack infusion project was established and commenced construction in the Liangcun Economic and Technological Development Zone in Shijiazhuang. From project approval to completion, the entire process took just over ten months, thereby filling a gap in the province’s plastic infusion bottle market. The first phase of the project was completed and put into operation within eight months, generating an additional RMB 100 million in annual sales revenue and RMB 24 million in additional profits and taxes for the company.

The company has been restructured from a state-controlled enterprise into a private enterprise.

In December 2001, against the backdrop of state-owned enterprises withdrawing from generally competitive sectors, the company seized the opportunity presented by Shijiazhuang’s pilot program for SOE restructuring and became the first to successfully transition from a state-controlled enterprise to a private enterprise, thereby marking the dawn of a new era of reform.

Company’s Intravenous Infusion Product Line Receives Hebei Province’s “First” National GMP Certificate

The company’s intravenous infusion production line has obtained Hebei Province’s “first” National GMP Certificate.

Shijiazhuang Sihua Pharmaceutical Co., Ltd. Established

In 1994, Sihua Pharmaceutical took the lead in implementing a shareholding system reform and established Shijiazhuang Sihua Pharmaceutical Co., Ltd., thereby laying the foundation for its future development.

“The ‘Shimen’ brand 10% glucose injection” was awarded the nation’s highest honor at the time—the title of “National Ministry-Level Superior Product.”

The company’s intravenous infusion product line: “Shimen” brand 10% glucose injection was awarded the nation’s highest honor at the time—the title of “National Ministry-Level Superior Product”—and the “Shimen” brand large-volume parenteral solutions became a well-known brand throughout the national healthcare system.

“The Shimen” Trademark Recognized as a Well-Known Trademark of Hebei Province

The “Shimen” trademark has, for the first time, been awarded the title of Famous Trademark of Hebei Province.

The name “Shijiazhuang Fourth Pharmaceutical Factory” is officially adopted.

Shijiazhuang Sanitary Materials Factory was officially renamed “Shijiazhuang No. 4 Pharmaceutical Factory,” becoming a key enterprise in Hebei Province for large-volume parenteral solutions and sanitary materials.

The “Shimen” trademark has been officially registered.

The “Shimen” trademark, sharing the same name as Shijiazhuang’s former appellation, has been officially registered, symbolizing the historical ties between Sihua Pharmaceutical and the development of Shijiazhuang and serving as a testament to the evolution of Shijiazhuang’s national industry.

Production of the flagship product, large-volume infusions, has officially commenced.

The company’s flagship product, large-volume parenteral solutions, has been in formal production, with a manufacturing history spanning more than fifty years to date.

The name “Shijiazhuang Municipal Sanitary Materials Factory” is officially adopted.

The factory’s name was changed to “Shijiazhuang Municipal Sanitary Materials Factory,” and it produces sanitary products such as medicinal cotton and medical adhesive tape.

“The ‘Three-Three Cotton-Gauze Cooperative’ was transformed into a locally state-owned degreased cotton factory.”

As the People’s Republic of China advanced, the “San San Degreased Cotton Cooperative” gradually emerged as a vital component of the state-owned economy and, upon approval, was transformed into a locally owned degreased cotton factory.

Shijiazhuang Sihua Pharmaceutical’s earliest-registered trademark—“Red Star”—has been successfully registered.

In 1949, the “Sansan Degreasing Cotton Cooperative” registered its first trademark—“Red Star.” Reflecting the historical context of the early years of the People’s Republic of China in the home textile sector, the “Red Star” trademark became the earliest trademark ever registered in the history of Shijiazhuang Fourth Pharmaceutical.

“The ‘Three-Three’ Cotton Wool Cooperative” Established

On March 6, 1948, amid the thunderous cannon fire marking the liberation of Shijiazhuang, the “3-3 Cotton-Gauze Cooperative,” founded by a handful of large cooking pots and twenty-six local citizens, laid the very first cornerstone of Shijiazhuang No. 4 Pharmaceutical Company—and thus forged an enduring bond with China’s pharmaceutical industry.